Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,535 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TIPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/β-catenin pathway.
Zhu L, Zhang X, Fu X, Li Z, Sun Z, Wu J, Wang X, Wang F, Li X, Niu S, Ding M, Yang Z, Yang W, Yin M, Zhang L, Zhang M. Zhu L, et al. Among authors: ding m. J Transl Med. 2018 Jan 17;16(1):7. doi: 10.1186/s12967-018-1383-0. J Transl Med. 2018. Retraction in: J Transl Med. 2024 Oct 28;22(1):977. doi: 10.1186/s12967-024-05795-3 PMID: 29343267 Free PMC article. Retracted.
Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure.
Hu J, Wang X, Chen F, Ding M, Dong M, Yang W, Yin M, Wu J, Zhang L, Fu X, Sun Z, Li L, Wang X, Li X, Guo S, Zhang D, Lu X, Leng Q, Zhang M, Zhu L, Zhang X, Chen Q. Hu J, et al. Among authors: ding m. Front Oncol. 2021 Jun 18;11:687374. doi: 10.3389/fonc.2021.687374. eCollection 2021. Front Oncol. 2021. PMID: 34222013 Free PMC article.
Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial.
Wu J, Gao F, Wang W, Zhang X, Dong M, Zhang L, Li X, Li L, Sun Z, Wang X, Fu X, Zhu L, Ding M, Niu S, Li Z, Chang Y, Nan F, Yan J, Yu H, Wu X, Zhou Z, Zhang J, Zhang M. Wu J, et al. Among authors: ding m. Cancer Biol Med. 2021 Oct 12;19(7):1089-99. doi: 10.20892/j.issn.2095-3941.2021.0026. Online ahead of print. Cancer Biol Med. 2021. PMID: 34633776 Free PMC article.
Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.
Wu JJ, Wang WH, Dong M, Ma SS, Zhang XD, Zhu LN, Niu ST, Ding MJ, Zhang JM, Zhang L, Li X, Li L, Sun ZC, Wang XH, Fu XR, Li ZM, Chang Y, Nan FF, Yan JQ, Yu H, Wu XL, Zhou ZY, Zhang MZ. Wu JJ, et al. Among authors: ding mj. Invest New Drugs. 2022 Jun;40(3):650-659. doi: 10.1007/s10637-022-01219-5. Epub 2022 Feb 9. Invest New Drugs. 2022. PMID: 35137332
Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial.
Wang X, Zhang L, Liu X, Li X, Li L, Fu X, Sun Z, Wu J, Zhang X, Yan J, Chang Y, Nan F, Zhou Z, Wu X, Tian L, Ma M, Li Z, Yu H, Zhu L, Wang Y, Shi C, Feng X, Li J, Ding M, Zhang J, Dong M, Xue H, Wang J, Zou L, Su L, Wu J, Liu L, Bao H, Zhang L, Guo Y, Guo S, Lu Y, Young KH, Li W, Zhang M. Wang X, et al. Among authors: ding m. JAMA Oncol. 2022 Jul 1;8(7):1035-1041. doi: 10.1001/jamaoncol.2022.1968. JAMA Oncol. 2022. PMID: 35708709 Free PMC article. Clinical Trial.
4,535 results